Pre-connect congress Ideate. Innovate. Integrate. 27th November
Pre-connect congress Ideate. Innovate. Integrate. 27th November 2017 The Westin, Mumbai Agenda 9:00 am-10:00 am
Registrations & Networking
10:00 am-10:20 am
Welcome Address Michael Duck, Executive Vice President of UBM Asia Limited, UBM Group Chief Representative for China, UBM Plc.
10:20 am-10:50 am
Chief Guest Address Industry update: Through the regulator’s lens The address will highlight the changing landscape of Indian regulatory policies. - Role of government in strengthening the regulatory systems - Steps taken to collaborate with the USFDA and EMEA - Impact of new drug policy on pricing and pharmaceutical industry
10:50 am-11:50 pm
Panel Discussion 1: Vision 2020: Gearing up for the next phase of growth While a blueprint has been laid down for ‘Pharma Vision 2020’ aimed at making India one of the leading destinations for end-to-end drug discovery and innovation, the government at its end continues to provide support by way of world class infrastructure, internationally competitive scientific manpower for pharma R&D and venture fund for research in the public and private domain. However, as an industry how can we gear up to make Pharma Vision 2020 a reality. -Unearthing key Indian and global trends in the Indian pharmaceutical industry -Disruptive technologies transforming pharmaceutical industry -Analysing existing gaps in the pharmaceutical industry -Impact of GST on the Indian pharmaceutical industry -Leveraging big data’s big dividends -Strategies to capitalize on biosimilars, speciality drugs and niche molecules -Maximizing revenues on medical tourism Jitendra Tyagi, Managing Director, Bristol- Myers Squibb India Pvt. Ltd. Manoj Saxena, Managing Director Bayer Zydus Pharma and South Asia Head at Bayer Pharma, Bayer Ramesh Swaminathan, Chief Financial Officer & Executive Director on the Board, Lupin Ltd. Srini Srinivasan, Managing Director, Hospira Healthcare India Pvt. Ltd. Suresh Pattathil, Chief Executive Officer, Ferring Pharmaceuticals Vivek Kamath, Managing Director, Merck Sharp & Dohme (MSD) Pharmaceuticals Pvt. Ltd. MODERATOR: Sujay Shetty, Partner and Leader, Pharmaceuticals and Life Sciences, PwC
11:50 pm-12:00 pm
Audience Interaction
12:00 pm-12:15 pm
Tea & Networking
12:15 pm-12:30 pm
DOW Corning
12:30 pm-12:45 pm
India pharma: A legal perspective -Contracts -Agreements -Dispute management -Patents
12:45 pm-1:45 pm
Networking Lunch Panel Discussion 2: Fostering innovation and creativity to make India the next hub for pharmaceutical R&D Recently, Indian pharmaceutical companies are seen investing substantially in R&D programs, as compared to previous years. This trend is seen not only in the case of generic drugs, but Indian pharmaceutical companies have increased (R&D) investments in lucrative specialty drugs and complex generics as well. -Leveraging the PPP model to propel India as an emerging R&D hub -Channelizing investments in R&D infrastructure to maximize revenue and returns -Methods to explore environmentally sustainable process design -Incentivization policies from government -Overcoming effects of price controls on R&D research -Exploring opportunities for clinical trials -Teaching an old drug new tricks
1:45 pm-2:45 pm
Dr. Anthony Melvin Crasto, Principle Scientist-Process Research, Glenmark Pharmaceuticals Dr. Ashok Kumar, President – Centre for Research & Development, Ipca Laboratories Ltd. Dr. Rajeev Singh Raghuvanshi, Senior Vice President and Global Head – CMC Differentiated Formulations R&D, Proprietary Product, Dr. Reddy’s Laboratories Ltd. Dr. Rajiv Sharma, Senior Vice President and Head of Chemistry, Zydus Research Center, Zydus Ramesh Matur, Senior Vice President and Head, Research & Development, Biological E Ltd. Dr. Sreehari Babu Putchakayala, Vice President & Head of Formulation & Analytical Development Services, GVK Biosciences Dr. Vinay Gopal Nayak, Executive Director, Marksans Pharma MODERATOR: Dr. Dhileep Krishnamurthy, Chief Scientific Officer, Zhejiang Nhu Company Ltd.
2:45 pm-2:55 pm
Audience interaction
2:55 pm-3:10 pm
Tea & Networking
3:10 pm-4:10 pm
Panel Discussion 3: Bridging the talent gap in the pharmaceutical and biopharmaceutical industry Talent acquisition has always been an overarching concern for most organizations. When it comes to pharmaceuticals and biopharmaceuticals, the sheer requirement of technically skilled workforce adds to the woes. While many organizations are now devising effective
strategies to bridge the talent dearth, it still seems that we have a long way to go. -Strategies to train and retain personnel -Talent acquisition in times of transition -Industry-academia partnerships -Integrating diversity and inclusion initiatives in building a gender diverse workforce (D&I) -Global best practices Amitava Saha, Sr. Vice President & Head - Human Resources, Biocon Dr. Mallikharjun Nagineni, Senior Vice President-HR, Mylan Laboratories Ltd. Mona Hakeem, VP - HR Head for Emerging Markets & Global Talent Acquisition, Sun Pharmaceutical Industries Ltd. Ravneet Bhanot, HR head for Global Drug Development, Novartis Rishikesh Raval, Senior Vice President-HR, Cadila Healthcare Ltd (Zydus Cadila) Ronal Sequeira, Country Head-HR, GlaxoSmithKline (GSK) Pharmaceuticals MODERATOR: Dr. Wayne Brockbank, Clinical Professor of Business, Ross School of Business, University of Michigan 4:10 pm-4:20 pm
Audience Interaction Panel Discussion 4: Building and sustaining a culture of quality Implementing and maintaining a culture of quality begins with a comprehensive evaluation of the various organizational, procedural, staffing, and other parameters that impact quality within the organization. The panel discussion will explore: -Strategies to maintain a leadership emphasis on quality -Ensuring accountability and credibility -Encouraging continuous improvement and quality assurance -Discussing best practices in quality
4:20 pm-5:20 pm Ganadhish Kamat, Executive Vice President & Global Quality Head, Dr. Reddy’s Laboratories Ltd. Dr. Rajiv Desai, Executive Vice President-Global Quality Head, Lupin Ltd. Dr. Ranjana Pathak, Global Head – Quality, Cipla Ltd. Rashida Najmi, Sr. VP – Global Quality & Pharmacovigilance, Nicholas Piramal India Ltd. Umesh Kale, President & Chief Quality Officer, Strides Shasun Ltd. 5:20 pm-5:30 pm
Audience Interaction
5:30 pm-5:35 pm
Closing Remarks
Registrations & Networking
10:00 am-10:20 am
Welcome Address Michael Duck, Executive Vice President of UBM Asia Limited, UBM Group Chief Representative for China, UBM Plc.
10:20 am-10:50 am
Chief Guest Address Industry update: Through the regulator’s lens The address will highlight the changing landscape of Indian regulatory policies. - Role of government in strengthening the regulatory systems - Steps taken to collaborate with the USFDA and EMEA - Impact of new drug policy on pricing and pharmaceutical industry
10:50 am-11:50 pm
Panel Discussion 1: Vision 2020: Gearing up for the next phase of growth While a blueprint has been laid down for ‘Pharma Vision 2020’ aimed at making India one of the leading destinations for end-to-end drug discovery and innovation, the government at its end continues to provide support by way of world class infrastructure, internationally competitive scientific manpower for pharma R&D and venture fund for research in the public and private domain. However, as an industry how can we gear up to make Pharma Vision 2020 a reality. -Unearthing key Indian and global trends in the Indian pharmaceutical industry -Disruptive technologies transforming pharmaceutical industry -Analysing existing gaps in the pharmaceutical industry -Impact of GST on the Indian pharmaceutical industry -Leveraging big data’s big dividends -Strategies to capitalize on biosimilars, speciality drugs and niche molecules -Maximizing revenues on medical tourism Jitendra Tyagi, Managing Director, Bristol- Myers Squibb India Pvt. Ltd. Manoj Saxena, Managing Director Bayer Zydus Pharma and South Asia Head at Bayer Pharma, Bayer Ramesh Swaminathan, Chief Financial Officer & Executive Director on the Board, Lupin Ltd. Srini Srinivasan, Managing Director, Hospira Healthcare India Pvt. Ltd. Suresh Pattathil, Chief Executive Officer, Ferring Pharmaceuticals Vivek Kamath, Managing Director, Merck Sharp & Dohme (MSD) Pharmaceuticals Pvt. Ltd. MODERATOR: Sujay Shetty, Partner and Leader, Pharmaceuticals and Life Sciences, PwC
11:50 pm-12:00 pm
Audience Interaction
12:00 pm-12:15 pm
Tea & Networking
12:15 pm-12:30 pm
DOW Corning
12:30 pm-12:45 pm
India pharma: A legal perspective -Contracts -Agreements -Dispute management -Patents
12:45 pm-1:45 pm
Networking Lunch Panel Discussion 2: Fostering innovation and creativity to make India the next hub for pharmaceutical R&D Recently, Indian pharmaceutical companies are seen investing substantially in R&D programs, as compared to previous years. This trend is seen not only in the case of generic drugs, but Indian pharmaceutical companies have increased (R&D) investments in lucrative specialty drugs and complex generics as well. -Leveraging the PPP model to propel India as an emerging R&D hub -Channelizing investments in R&D infrastructure to maximize revenue and returns -Methods to explore environmentally sustainable process design -Incentivization policies from government -Overcoming effects of price controls on R&D research -Exploring opportunities for clinical trials -Teaching an old drug new tricks
1:45 pm-2:45 pm
Dr. Anthony Melvin Crasto, Principle Scientist-Process Research, Glenmark Pharmaceuticals Dr. Ashok Kumar, President – Centre for Research & Development, Ipca Laboratories Ltd. Dr. Rajeev Singh Raghuvanshi, Senior Vice President and Global Head – CMC Differentiated Formulations R&D, Proprietary Product, Dr. Reddy’s Laboratories Ltd. Dr. Rajiv Sharma, Senior Vice President and Head of Chemistry, Zydus Research Center, Zydus Ramesh Matur, Senior Vice President and Head, Research & Development, Biological E Ltd. Dr. Sreehari Babu Putchakayala, Vice President & Head of Formulation & Analytical Development Services, GVK Biosciences Dr. Vinay Gopal Nayak, Executive Director, Marksans Pharma MODERATOR: Dr. Dhileep Krishnamurthy, Chief Scientific Officer, Zhejiang Nhu Company Ltd.
2:45 pm-2:55 pm
Audience interaction
2:55 pm-3:10 pm
Tea & Networking
3:10 pm-4:10 pm
Panel Discussion 3: Bridging the talent gap in the pharmaceutical and biopharmaceutical industry Talent acquisition has always been an overarching concern for most organizations. When it comes to pharmaceuticals and biopharmaceuticals, the sheer requirement of technically skilled workforce adds to the woes. While many organizations are now devising effective
strategies to bridge the talent dearth, it still seems that we have a long way to go. -Strategies to train and retain personnel -Talent acquisition in times of transition -Industry-academia partnerships -Integrating diversity and inclusion initiatives in building a gender diverse workforce (D&I) -Global best practices Amitava Saha, Sr. Vice President & Head - Human Resources, Biocon Dr. Mallikharjun Nagineni, Senior Vice President-HR, Mylan Laboratories Ltd. Mona Hakeem, VP - HR Head for Emerging Markets & Global Talent Acquisition, Sun Pharmaceutical Industries Ltd. Ravneet Bhanot, HR head for Global Drug Development, Novartis Rishikesh Raval, Senior Vice President-HR, Cadila Healthcare Ltd (Zydus Cadila) Ronal Sequeira, Country Head-HR, GlaxoSmithKline (GSK) Pharmaceuticals MODERATOR: Dr. Wayne Brockbank, Clinical Professor of Business, Ross School of Business, University of Michigan 4:10 pm-4:20 pm
Audience Interaction Panel Discussion 4: Building and sustaining a culture of quality Implementing and maintaining a culture of quality begins with a comprehensive evaluation of the various organizational, procedural, staffing, and other parameters that impact quality within the organization. The panel discussion will explore: -Strategies to maintain a leadership emphasis on quality -Ensuring accountability and credibility -Encouraging continuous improvement and quality assurance -Discussing best practices in quality
4:20 pm-5:20 pm Ganadhish Kamat, Executive Vice President & Global Quality Head, Dr. Reddy’s Laboratories Ltd. Dr. Rajiv Desai, Executive Vice President-Global Quality Head, Lupin Ltd. Dr. Ranjana Pathak, Global Head – Quality, Cipla Ltd. Rashida Najmi, Sr. VP – Global Quality & Pharmacovigilance, Nicholas Piramal India Ltd. Umesh Kale, President & Chief Quality Officer, Strides Shasun Ltd. 5:20 pm-5:30 pm
Audience Interaction
5:30 pm-5:35 pm
Closing Remarks
